Skip to main content
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. — Investor Relations & Filings

Ticker · VKTX ISIN · US92686J1060 LEI · 529900IVC72YPFA25M37 US Professional, scientific and technical activities
Open in API
Filings indexed 608 across all filing types
Latest filing 2024-03-26 Regulatory Filings
Country US United States of America
Listing US VKTX

About Viking Therapeutics, Inc.

https://vikingtherapeutics.com/

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's pipeline is centered on small molecule drug candidates designed to address these conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 26, 2024. It announces the issuance of a press release regarding clinical trial results. The document is short (3448 characters) and primarily serves to furnish a press release as an exhibit. There are no financial statements or detailed financial data included. The document is an announcement of information rather than a full report or detailed filing. According to the rules, such short filings that announce or furnish a press release or report are classified as Regulatory Filings (RNS).
2024-03-26 English
FORM 4 SUBMISSION
Director's Dealing
2024-03-05 English
FORM 4 SUBMISSION
Director's Dealing
2024-03-05 English
FORM 4 SUBMISSION
Director's Dealing
2024-03-05 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 4, 2024. It announces the closing of a previously announced underwritten public offering of common stock shares by Viking Therapeutics, Inc. The content focuses on a financing event, specifically the sale of shares and the exercise of underwriters' option. There are no financial statements or detailed financial performance data included, only an announcement of a capital raising event. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). The document length is 3407 characters, which is short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2024-03-04 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of 6,471,000 shares of common stock, including pricing, underwriting discounts, use of proceeds, risk factors, and other offering-related information. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, or management discussion. It is clearly related to a financing activity and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear nature of the document as a prospectus supplement for a stock offering.
2024-03-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.